Additionally, a new GLP-1 candidate, pemvidutide, has recently shown weight reductions in a Phase 2 trial with a lower percentage of muscle loss compared to other GLP-1s
This is actually a matter of some debate, and part of it comes down to semantics
theyve been tested in big studies and are helping real people every day
While official estimates point to a relatively contained user base, actual use may be materially higher given the presence of parallel and informal supply channels
*This result was not the primary goal of the medical study and should be considered as additional information
Confirm the open items above (exact medical group entity, pharmacy compounding framework, insurance) directly with Zevay before treating the program as fully vetted